Notice of AGM & availability of 2026 Annual Report
![]()
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Annual General Meeting
&
Availability of 2026 Annual Report
York, UK and Madison, WI, USA, 11 November 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, confirms that its Annual General Meeting ('AGM') will be held on 25 November 2026 at 10.00 GMT at the Company's offices at York Biotech Campus, Sand Hutton, York, YO41 1LZ, United Kingdom.
The Company confirms that its 2026 Annual Report and Notice of the AGM have been available on the Company's website www.abingdonhealth.com since 13 October 2026 and 14 October 2026, respectively. Printed copies of both documents have been posted to registered shareholders who have elected to receive paper communications.
Enquiries:
|
Abingdon Health plc |
||
|
Chris Hand, Executive Chairman
|
Via Walbrook PR |
|
|
Tom Hayes, CFO
|
|
|
|
|
|
|
|
Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser) |
Tel: +44 (0)20 7220 0500 |
|
|
Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance) Nigel Birks (Life Science Specialist Sales) |
|
|
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|

About Abingdon Health
Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.
The Group’s CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory strategy support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.
Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company’s subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.
Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.
Abingdon Health's brochures outlines the comprehensive support the Group can now provide to its international customers. For more information visit: www.abingdonhealth.com.
LEI - 213800XFI4WV3FBILO20
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).
Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.
Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.
All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.
This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.
This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.
FOR OUR FULL DISCLAIMER CLICK HERE